pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Nurix Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Nurix Therapeutics.
Nurix Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
Relapsed/Refractory B-cell Malignancies
1 trial -
Drug Product De-TIL-0255
Nurix Therapeutics
Platinum-resistant Ovarian Cancer
1 trial -
IP
Nurix Therapeutics
Healthy Volunteers
1 trial -
NX-1607
Nurix Therapeutics
Ovarian Cancer, Epithelial
1 trial -
NX-2127
Nurix Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial -
NX-5948
Nurix Therapeutics
Healthy Volunteer
2 trials
Frequently asked questions
How many clinical projects does Nurix Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.